Amryt Pharma (Amryt Pharma) EPS (Basic) : $-0.30 (TTM As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma EPS (Basic)?

Amryt Pharma's basic earnings per share (Basic EPS) for the three months ended in Sep. 2022 was $-0.30. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.30.

Amryt Pharma's EPS (Diluted) for the three months ended in Sep. 2022 was $-0.30. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.30.

Amryt Pharma's EPS without NRI for the three months ended in Sep. 2022 was $-0.30. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2022 was -0.30.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Amryt Pharma's highest 3-Year average EPS without NRI Growth Rate was 7.90% per year. The lowest was -164.00% per year. And the median was -71.15% per year.

Amryt Pharma EPS (Basic) Historical Data

The historical data trend for Amryt Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma EPS (Basic) Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Basic)

Get a 7-Day Free Trial

-4.22

-3.33

-4.15

-3.30

0.02

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EPS (Basic)	Get a 7-Day Free Trial															-0.35	0.35	-0.25	-0.10	-0.30

Amryt Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Amryt Pharma's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(1	-	0)	/	47.170
	=	0.02

Amryt Pharma's Basic EPS for the quarter that ended in Sep. 2022 is calculated as

Basic EPS (Q: Sep. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-20.795	-	0)	/	64.046
	=	-0.32

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30

Amryt Pharma (NAS:AMYT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Amryt Pharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).